SEATTLE, WA, Jan 6, 2025 - (ACN Newswire) - Spectral Capital Corporation (OTCQB: FCCN), a pioneer in Quantum as a Service (QaaS) computing and decentralized cloud infrastructure, is pleased to announce the achievement of a major patent milestone as the first step in its plan…
![Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma](https://www.so-co-it.com/wp-content/themes/socoit20/timthumb.php?src=wp-content%2Fuploads%2F716035.jpg&q=90&w=460&h=260&zc=1%20width=460%20height=260)
Back to media releases (https://norgine.com/media) Next media release (https://norgine.com/press_release/norgine-receives-positive-chmp-opinion-recommending-approval-of-npj5008-dantrolene-sodium-hemiheptahydrate-for-the-treatment-of-malignant-hyperthermia/) Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, i…
As part of the EU-funded APRIORA project, drug residues are being analysed. Scientists from the University of Rostock are taking water samples in all weathers. The aim is to use innovative approaches to improve wastewater treatment in Europe. The Warnow seems to be flowing…
ZEISS Group revenue increased to just under 11 billion euros (10.894 billion euros), (up 8% on the prior year) – EBIT 1,444 million euros (prior year: 1,686 million euros, EBIT margin 13%). Mixed development in the segments. High spend on research and development equivalent to…
- Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October 2024 by the Committee…
Lissi GmbH has qualified for the final phase of the EUDI-Wallet prototype competition organised by the German Federal Agency for Leap Innovation (SPRIND). The competition promotes innovative solutions for the implementation of the European eIDAS 2.0 regulation. “We are proud to have once again convinced…
Spectral Achieves Major Patent Milestone Related to Quantum Computing
SEATTLE, WA, Jan 6, 2025 - (ACN Newswire) - Spectral Capital Corporation (OTCQB: FCCN), a…
![Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma](https://www.so-co-it.com/wp-content/themes/socoit20/timthumb.php?src=wp-content%2Fuploads%2F716035.jpg&q=90&w=230&h=105&zc=1%20width=230%20height=105)
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
Back to media releases (https://norgine.com/media) Next media release (https://norgine.com/press_release/norgine-receives-positive-chmp-opinion-recommending-approval-of-npj5008-dantrolene-sodium-hemiheptahydrate-for-the-treatment-of-malignant-hyperthermia/) Norgine today announced that it completed its marketing…
Assessing risks from pharmaceutical residues: How the APRIORA project is helping communities to improve drinking water quality
As part of the EU-funded APRIORA project, drug residues are being analysed. Scientists from the…
ULVAC Launches New Deposition System for Semiconductor Applications: Model “ENTRON-EXX”
Supporting Enhanced Productivity and Accelerated Development Speed with Advanced Data Collection, Analysis Capabilities, and Expandability.…
Mitsubishi Electric Swedish Subsidiary Signs a Share Transfer Agreement to Wholly Acquire Norwegian Elevator Company ALT Heis
Aiming to further strengthen the company-s elevator and escalator business in Europe via M&A…
Encouraging people to protect the earth / DBU honours Franziska Tanneberger and Thomas Speidel
Ways to better protect the planet are currently being debated at the World Summit on…
![Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma](https://www.so-co-it.com/wp-content/themes/socoit20/timthumb.php?src=wp-content%2Fuploads%2F716035.jpg&q=90&w=223&h=105&zc=1%20width=223%20height=105)
Recent Comments